Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Novel Three-Way Translocation Involving ETV6-IL3 Drives AML with Eosinophilia

Ariel Siegel, Joseph Tripodi, Brianna Kelly, Sebastian Elghaity-Beckley, Michelle Becker, Douglas Tremblay, Jonathan Feld, Hannah Levavi, Marina Kremyanskaya, Bridget Kelly Marcellino, Christian Salib, Alla Keyzner, Amy Duffield, John O. Mascarenhas, Vesna Najfeld, Alan Shih

Blood (2024) 144 (Supplement 1): 6098.

https://doi.org/10.1182/blood-2024-203588

Published: 2024

Journal Articles

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Blood (2024) 144 (Supplement 1): 924.

https://doi.org/10.1182/blood-2024-201526

Published: 2024

Journal Articles

Initial Results of a Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Prevent Relapse after Allogeneic Hematopoietic Cell Transplantation

Monzr M. Al Malki, Alla Keyzner, Hyung Chan Suh, Aasiya Matin, Erica Buonomo, Yun Wang, Nina Abelowitz, Jim Murray, Gavin Macbeath, Debora Barton, Shrikanta Chattopadhyay, Ran Reshef

Blood (2023) 142 (Supplement 1): 2090.

https://doi.org/10.1182/blood-2023-187355

Published: 2023

Journal Articles

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

Blood (2023) 142 (Supplement 1): 3181.

https://doi.org/10.1182/blood-2023-173441

Published: 2023

Journal Articles

Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers

Blood (2022) 140 (Supplement 1): 7731–7733.

https://doi.org/10.1182/blood-2022-157985

Published: 2022

Journal Articles

Central Nervous System Specific Characteristics and Outcomes in Acute Myeloid Leukemia Patients with Neurologic Involvement

Dahniel Sastow, Yosef J.R.A Riazat-Kesh, Kyle Farina, Jonathan Feld, Michal Bar-Natan, Alla Keyzner, Lewis R. Silverman, Marina Kremyanskaya, John Mascarenhas, Douglas Tremblay

Blood (2022) 140 (Supplement 1): 11618–11620.

https://doi.org/10.1182/blood-2022-157300

Published: 2022

Journal Articles

Prognostic Impact of Day 14 Bone Marrow (D14 BM Bx) in Acute Myeloid Leukemia (AML) in the Setting of European Leukemianet (ELN) Risk Classification

Metodi Balev, Nicole Zubizarreta, Erin Bresnahan, Jonathan Feld, Marina Kremyanskaya, Alla Keyzner, Alan H. Shih, Bridget K Marcellino, Lewis R. Silverman, Michal Bar-Natan, John Mascarenhas, Douglas Tremblay

Blood (2022) 140 (Supplement 1): 139–140.

https://doi.org/10.1182/blood-2022-167828

Published: 2022

Journal Articles

No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial

Filippo Milano, MD PhD, Andrew R Rezvani, MD, Joanne Kurtzberg, MD, Chatchada Karanes, MD, Jonathan A Gutman, MD, Christine Duncan, MD, Alla Keyzner, MD, Rabi Hanna, MD, Tonya Kimberly Marmon, PhD, Ann Dahlberg, MD, Colleen Delaney, MD MSc

Blood (2019) 134 (Supplement_1): 146.

https://doi.org/10.1182/blood-2019-130716

Published: 2019

Journal Articles

Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Douglas Tremblay, MD, Rafael Madero-Marroquin, MD, Guido Lancman, MD, Alexander Coltoff, MD, Jonathan Feld, MD, Jessica Caro, MD, Nicole Zubizarreta, MPH, Marina Kremyanskaya, Alla Keyzner, MD, Michal Bar-Natan, MD, Shyamala C. Navada, MD, Lewis R. Silverman, Janice L. Gabrilove, MD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 5102.

https://doi.org/10.1182/blood-2019-123288

Published: 2019

Journal Articles

Dose-Adjusted Intensive Chemotherapy Is Safe and Tolerable in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia

Anne S. Renteria, MD, Sangeetha Venugopal, MD, Bridget Marcellino, MD PhD, Alla Keyzner, MD, Marina Kremyanskaya, MD PhD, Vesna Najfeld, PhD, John Mascarenhas, MD

Blood (2018) 132 (Supplement 1): 5158.

https://doi.org/10.1182/blood-2018-99-115634

Published: 2018

Journal Articles

The Effect of JAK 1/2 Inhibitors on Outcomes of Allogeneic Stem Cell Transplantation for Patients with Myelofibrosis

Guido Lancman, MD, Kathleen Miller, MD, Shuli Li, PhD, Vincent T. Ho, MD, Amir T. Fathi, MD, Yi-Bin Chen, MD, Alla Keyzner, MD, Douglas Tremblay, MD, Anita Geevarghese, MD, Prapti Chatterjee, MD, Ronald Hoffman, MD, John Mascarenhas, MD, Gabriela S. Hobbs, MD

Blood (2018) 132 (Supplement 1): 5784.

https://doi.org/10.1182/blood-2018-99-112769

Published: 2018

Journal Articles

Preclinical Development of a Cord Blood (CB)-Derived Hematopoietic Stem Cell (HSC) Product for Allogeneic Transplantation in Patients with Hematological Malignancies

Camelia Iancu-Rubin, PhD, Helen Fong, PhD, Goar Mosoyan, Ami Patel, MS, Rachel Sabado, PhD, Meseck Marcia, MS, Erin Moshier, MS, Umut Ozbek, PhD, Alla Keyzner, MD, Nina Bhardwaj, MD PhD, Ian K. McNiece, PhD, Jay Tong, MD, Ronald Hoffman, MD

Blood (2016) 128 (22): 818.

https://doi.org/10.1182/blood.V128.22.818.818

Published: 2016

NARROW

A Novel Three-Way Translocation Involving ETV6-IL3 Drives AML with Eosinophilia

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Initial Results of a Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Prevent Relapse after Allogeneic Hematopoietic Cell Transplantation

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers

Central Nervous System Specific Characteristics and Outcomes in Acute Myeloid Leukemia Patients with Neurologic Involvement

Prognostic Impact of Day 14 Bone Marrow (D14 BM Bx) in Acute Myeloid Leukemia (AML) in the Setting of European Leukemianet (ELN) Risk Classification

No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial

Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Dose-Adjusted Intensive Chemotherapy Is Safe and Tolerable in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia

The Effect of JAK 1/2 Inhibitors on Outcomes of Allogeneic Stem Cell Transplantation for Patients with Myelofibrosis

Preclinical Development of a Cord Blood (CB)-Derived Hematopoietic Stem Cell (HSC) Product for Allogeneic Transplantation in Patients with Hematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only